156 related articles for article (PubMed ID: 29202237)
1. Impact of Solid-State Form on the Disproportionation of Miconazole Mesylate.
Patel MA; Luthra S; Shamblin SL; Arora K; Krzyzaniak JF; Taylor LS
Mol Pharm; 2018 Jan; 15(1):40-52. PubMed ID: 29202237
[TBL] [Abstract][Full Text] [Related]
2. Impact of Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State Formulations.
Nie H; Xu W; Ren J; Taylor LS; Marsac PJ; John CT; Byrn SR
Mol Pharm; 2016 Oct; 13(10):3541-3552. PubMed ID: 27542728
[TBL] [Abstract][Full Text] [Related]
3. The Effect of In-Situ-Generated Moisture on Disproportionation of Pharmaceutical Salt.
Weldeab AO; McElderry JD; Lin Y
Mol Pharm; 2023 Jan; 20(1):561-571. PubMed ID: 36524757
[TBL] [Abstract][Full Text] [Related]
4. Effect of excipient properties, water activity, and water content on the disproportionation of a pharmaceutical salt.
Patel MA; Luthra S; Shamblin SL; Arora KK; Krzyzaniak JF; Taylor LS
Int J Pharm; 2018 Jul; 546(1-2):226-234. PubMed ID: 29772284
[TBL] [Abstract][Full Text] [Related]
5. Crystalline solid dispersion-a strategy to slowdown salt disproportionation in solid state formulations during storage and wet granulation.
Nie H; Xu W; Taylor LS; Marsac PJ; Byrn SR
Int J Pharm; 2017 Jan; 517(1-2):203-215. PubMed ID: 27979765
[TBL] [Abstract][Full Text] [Related]
6. Salt stability--effect of particle size, relative humidity, temperature and composition on salt to free base conversion.
Hsieh YL; Taylor LS
Pharm Res; 2015 Feb; 32(2):549-61. PubMed ID: 25145335
[TBL] [Abstract][Full Text] [Related]
7. Quantifying Disproportionation in Pharmaceutical Formulations with
Hirsh DA; Su Y; Nie H; Xu W; Stueber D; Variankaval N; Schurko RW
Mol Pharm; 2018 Sep; 15(9):4038-4048. PubMed ID: 30016112
[TBL] [Abstract][Full Text] [Related]
8. Salt Stability - The Effect of pHmax on Salt to Free Base Conversion.
Hsieh YL; Merritt JM; Yu W; Taylor LS
Pharm Res; 2015 Sep; 32(9):3110-8. PubMed ID: 25874534
[TBL] [Abstract][Full Text] [Related]
9. Disproportionation of Pharmaceutical Salts: pH
Avdeef A
Mol Pharm; 2021 Jul; 18(7):2724-2743. PubMed ID: 34142831
[TBL] [Abstract][Full Text] [Related]
10. Stability of pharmaceutical salts in solid oral dosage forms.
Nie H; Byrn SR; Zhou QT
Drug Dev Ind Pharm; 2017 Aug; 43(8):1215-1228. PubMed ID: 28276282
[TBL] [Abstract][Full Text] [Related]
11. Role of salt and excipient properties on disproportionation in the solid-state.
Guerrieri P; Taylor LS
Pharm Res; 2009 Aug; 26(8):2015-26. PubMed ID: 19507008
[TBL] [Abstract][Full Text] [Related]
12. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
[TBL] [Abstract][Full Text] [Related]
13. Disproportionation of the calcium salt of atorvastatin in the presence of acidic excipients.
Christensen NP; Rantanen J; Cornett C; Taylor LS
Eur J Pharm Biopharm; 2012 Oct; 82(2):410-6. PubMed ID: 22824098
[TBL] [Abstract][Full Text] [Related]
14. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation.
Merritt JM; Viswanath SK; Stephenson GA
Pharm Res; 2013 Jan; 30(1):203-17. PubMed ID: 22918819
[TBL] [Abstract][Full Text] [Related]
15. Effect of Excipients on Salt Disproportionation during Dissolution: A Novel Application of In Situ Raman Imaging.
Abouselo A; Rance GA; Tres F; Taylor LS; Kwokal A; Renou L; Scurr DJ; Burley JC; Aylott JW
Mol Pharm; 2021 Sep; 18(9):3247-3259. PubMed ID: 34399050
[TBL] [Abstract][Full Text] [Related]
16. Impact of sertraline salt form on the oxidative stability in powder blends.
Hsieh YL; Yu W; Xiang Y; Pan W; Waterman KC; Shalaev EY; Shamblin SL; Taylor LS
Int J Pharm; 2014 Jan; 461(1-2):322-30. PubMed ID: 24325937
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Influence of Excipients on the Stability of Levothyroxine Sodium Pentahydrate.
Kaur N; Suryanarayanan R
Mol Pharm; 2021 Jul; 18(7):2683-2693. PubMed ID: 34061524
[TBL] [Abstract][Full Text] [Related]
18. Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate.
Gu CH; Gandhi RB; Tay LK; Zhou S; Raghavan K
Int J Pharm; 2004 Jan; 269(1):195-202. PubMed ID: 14698591
[TBL] [Abstract][Full Text] [Related]
19. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
20. Miniaturized approach for excipient selection during the development of oral solid dosage form.
Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
